Coronavirus Disease 2019 (COVID-19) is the greatest public health challenge in over a century. Basic questions about its prevention, diagnosis, treatment and prognosis remain unanswered, hindering evidence-based clinical decision-making.
In Year 1 (June 1 2020-May 31 2021) we established a governance structure, signed Membership & Data Sharing Agreements, obtained Research Ethics Board (REB) and institutional approvals from all participating sites, completed Privacy Impact Assessments and data management plans, and initiated data collection.
We have completed analyses for two clinical decision rules (predicting COVID-19 test positivity & futility of intubation), a diagnostic test evaluation (screening asymptomatic admissions), and studies on gender, co-morbidity and phase of pandemic, which we will publish shortly.
In December 2020, we initiated data collection on vaccination status and vaccine effectiveness as we believe that vaccines will change the course of the pandemic and impact COVID-19 risk factors, outcomes and complications, as well as clinical and public health decision-making.
Of the 177 observational COVID-19 registries listed with the World Health Organization (WHO), CCEDRRN is the third-largest in the world.
Dr. Corinne Hohl
(Associate Professor, University of British Columbia; BC) is an emergency physician and health services researcher with expertise in multi-centre observational cohort studies and quasi-experimental designs. She holds over $13M in research funding as nominated Principal Applicant, with over 70 peer-reviewed publications.
Dr. Laurie Morrison
(Professor, University of Toronto) is a senior resuscitation scientist with experience in international networks, registries, randomized trials and clinical decision rules. She is Director of the Collaborative Specialization Resuscitation Sciences graduate training and mentorship, and will coordinate our graduate students and mentoring of Early Career Researchers.
Dr. Jeffrey Perry
(Professor, University of Ottawa) is a world-leading expert in clinical decision rules, and has derived, validated and implemented multiple influential emergency clinical decision rules.
In Year 2 (June 1 2021-March 31 2022), we aim to leverage our established infrastructure to create a national vaccine evaluation platform in partnership with provincial Public Health partners.
We will evaluate vaccine effectiveness (VE) and the duration of protection in priority populations who commonly receive care in Emergency Departments for symptomatic and severe COVID-19, and were inadequately evaluated in or excluded from phase 3 vaccine effectiveness trials.
Our specific objectives are to evaluate:
The effectiveness of COVID-19 vaccines for preventing severe COVID-19 in priority groups, including in racialized and Indigenous communities, individuals of lower socioeconomic status, those with active comorbidity (e.g., active cancer), at the extremes of ages, in pregnant and breastfeeding women, and in otherwise marginalized groups;
The effectiveness of COVID-19 vaccines in preventing severe disease, hospitalization and mortality, as delivered in the real-world, including single doses of vaccines authorized as two-dose series, delayed boosters, and receipt of vaccines from different manufacturers; and
The duration of vaccine protection from symptomatic COVID-19 in the general population and in specific groups (e.g., elderly with immune senescence), by vaccine type, for single doses of vaccines authorized as two-dose series, and in individuals receiving a delayed booster.
CCEDRRN is governed primarily by the Executive Committee which oversees the day-to-day operations of the network, and the Steering Committee which provides oversight and direction to the network.
CCEDRRN's governance structure provides for a robust, scientific peer-review process ensuring data integrity to allow for world-class, high-quality research published by the network.
The network is generously funded by: